<p>股市的一个伟大之处在于，优秀的股票几乎可以以任何价格购买，使大多数人都能接触到。即使只有 100 美元，也可以找到出色的、以增长为导向的公司进行投资。当然，什么样的股票被认为是 “最聪明” 的投资选择因投资者而异，这取决于风险承受能力、目标和投资期限等因素。</p>
<p>一只交易价格远低于 100 美元的成长股，能够满足许多投资者需求的是 <strong>诺和诺德</strong>（NVO -2.96%）。以下是这家总部位于丹麦的公司为何现在是一个优秀的买入股票的原因。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzY2MTgvcGF0aWVudC1zZWxmLWFkbWluaXN0ZXJpbmctYS1zaG90LmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzY2MTgvcGF0aWVudC1zZWxmLWFkbWluaXN0ZXJpbmctYS1zaG90LmpwZyZ3PTcwMA"/></p>
<p>图片来源：Getty Images。</p>
<h2>一个绝妙的逆向投资机会</h2>
<p>优质成长股往往备受追捧。这些公司的股票需求通常高于可用股票数量，这就是它们价格上涨的原因。然而，有时这些本来优秀的公司会遇到挑战，导致抛售，为投资者提供了以折扣价购买其股票的绝妙机会。</p>
<p>在我看来，这就是诺和诺德的现状。确实，该公司面临了一些挑战，并且由于股票价格在过去一年中持续下跌而付出了代价。其财务业绩未能达到预期。它在与竞争对手 <strong>礼来</strong> 的竞争中失去了市场份额，并遭遇了一系列意外的临床挫折。</p>
<p>然而，诺和诺德的前景依然非常强劲。诺和诺德的声誉在于它在糖尿病药物市场上已经占据了数十年的重要地位。到目前为止，它在糖尿病市场的份额为 32.6%，在 GLP-1 领域的份额为 51.9%。尽管与去年相比，它在这些领域的份额有所下降，但它在这两个领域仍然是一个主导力量。</p>
<p>诺和诺德在制药巨头中继续保持竞争力的财务业绩。该公司上半年的销售额同比增长了 16%，达到了 1549 亿丹麦克朗（242 亿美元）。</p>
<p>此外，由于多种因素，糖尿病和肥胖药物市场正在快速增长。这两种疾病在最近几十年中急剧上升，制药公司现在正在开发高度创新的疗法来应对这些问题。诺和诺德仍然处于这场竞争的前沿。即使该公司在市场中的份额较小，但如果市场整体规模大幅增加，这也不是一个重大问题。</p>
<p>诺和诺德能否继续推出创新药物，并在大多数竞争对手（不包括礼来）中保持领先？公司的研发管道表明它可以，甚至可能赶上其永恒的竞争对手。考虑一下诺和诺德的潜在三重激动剂（模仿三种肠道激素作用的药物）UBT251。</p>
<p>在一项为期 12 周的第一阶段研究中，UBT251 在最高剂量下平均减重 15.1%。关于早期研究的通常警告适用。然而，UBT251 看起来很有前景，特别是因为目前尚未批准任何单一的三重激动剂用于减重。这只是冰山一角。诺和诺德还有其他几个令人兴奋的候选药物正在进行各个阶段的临床开发。而那些已经通过三期研究的药物，如 CagriSema，应该为这家制药公司带来巨额销售。</p>
<p>根据一些预测，CagriSema 到 2030 年可能会实现 152 亿美元的收入。诺和诺德目前的畅销药物 Ozempic 和 Wegovy 预计在本十年末仍将保持全球畅销药物的地位。因此，诺和诺德的中期前景似乎乐观。</p>
<h2>还有更多购买理由</h2>
<p>诺和诺德吸引了以增长为导向的投资者，但对于寻求分红和捡便宜的投资者来说也是一个不错的选择。对于那些寻求收入股票的投资者来说，这家总部位于丹麦的制药公司是一个不错的选择，考虑到其强劲的业绩记录。该公司的前瞻性收益率虽然不算特别，只有 2.9%——尽管这比 <strong>标准普尔 500</strong> 的平均水平 1.3% 要好得多——但诺和诺德在过去十年中持续增加其分红。</p>
<p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/139c9b8375922eacc3348b2ceba36a5b.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/139c9b8375922eacc3348b2ceba36a5b.png"/></p>
<p>NVO 分红（年度）数据来源于 YCharts</p>
<p>最后，诺和诺德的股票交易价格为前瞻性收益的 14 倍，而医疗行业的平均水平为 17.3 倍。尽管最近面临挑战，诺和诺德强大的研发管道和产品组合、稳健的收入增长以及在糖尿病和体重管理方面的良好前景使得该股票极具吸引力。该公司的股票目前交易价格约为 59 美元，因此 100 美元可以购买到一股。</p>

诺和诺德公司

<p>诺和诺德公司 (NVO) 被认为是一个值得购买的顶级成长股，价格低于 100 美元，尽管近期面临挑战和股价下跌。该公司在糖尿病药物市场保持强劲地位，市场份额达到 32.6%。其销售额同比增长 16%，并且正在开发有前景的药物，包括 UBT251 和 CagriSema。以 14 的前瞻市盈率和 2.9% 的股息收益率，诺和诺德公司为寻求成长和收入的投资者提供了一个有吸引力的投资机会</p>

<p>One of the great things about equity markets is that excellent stocks can be had at almost any price, making them accessible to most people. Even with $100, it's possible to find outstanding, growth-oriented companies to invest in. Of course, what qualifies as &#34;the smartest&#34; stock to buy with any amount of money will differ from one investor to the next, depending on factors such as risk tolerance, goals, and investment horizon.</p>
<div class="lb-trans"><p>股市的一个伟大之处在于，优秀的股票几乎可以以任何价格购买，使大多数人都能接触到。即使只有 100 美元，也可以找到出色的、以增长为导向的公司进行投资。当然，什么样的股票被认为是 “最聪明” 的投资选择因投资者而异，这取决于风险承受能力、目标和投资期限等因素。</p>
</div><p>One growth stock trading for well below $100 that can meet many investors' demands is <strong>Novo Nordisk</strong>(NVO -2.96%). Here is why the Denmark-based company is an excellent stock to buy right now.</p>
<div class="lb-trans"><p>一只交易价格远低于 100 美元的成长股，能够满足许多投资者需求的是 <strong>诺和诺德</strong>（NVO -2.96%）。以下是这家总部位于丹麦的公司为何现在是一个优秀的买入股票的原因。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzY2MTgvcGF0aWVudC1zZWxmLWFkbWluaXN0ZXJpbmctYS1zaG90LmpwZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F836618%2Fpatient-self-administering-a-shot.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><h2>A wonderful contrarian opportunity</h2>
<div class="lb-trans"><h2>一个绝妙的逆向投资机会</h2>
</div><p>Quality growth stocks tend to be highly sought after. There is often a higher demand for shares of these companies than are available. That's why their prices rise. Sometimes, though, these otherwise excellent companies encounter challenges that lead to a sell-off, providing investors with a wonderful opportunity to pick up their shares at a discount.</p>
<div class="lb-trans"><p>优质成长股往往备受追捧。这些公司的股票需求通常高于可用股票数量，这就是它们价格上涨的原因。然而，有时这些本来优秀的公司会遇到挑战，导致抛售，为投资者提供了以折扣价购买其股票的绝妙机会。</p>
</div><p>In my view, that's what we have with Novo Nordisk. True, the company has faced some challenges, and it has paid for them as shares have remained southbound for over a year. Its financial results haven't been as strong as expected. It hit a series of surprising clinical setbacks while losing market share to its rival, <strong>Eli Lilly</strong>.</p>
<div class="lb-trans"><p>在我看来，这就是诺和诺德的现状。确实，该公司面临了一些挑战，并且由于股票价格在过去一年中持续下跌而付出了代价。其财务业绩未能达到预期。它在与竞争对手 <strong>礼来</strong> 的竞争中失去了市场份额，并遭遇了一系列意外的临床挫折。</p>
</div><p>However, Novo Nordisk's prospects remain very strong. Novo Nordisk's claim to fame is that it has been a major player in the diabetes drug market for decades. That remains the case. As of May, it had a 32.6% share of the diabetes market and a 51.9% share of the GLP-1 space. While its hold in these fields declined compared to last year, it remains a dominant force in both.</p>
<div class="lb-trans"><p>然而，诺和诺德的前景依然非常强劲。诺和诺德的声誉在于它在糖尿病药物市场上已经占据了数十年的重要地位。到目前为止，它在糖尿病市场的份额为 32.6%，在 GLP-1 领域的份额为 51.9%。尽管与去年相比，它在这些领域的份额有所下降，但它在这两个领域仍然是一个主导力量。</p>
</div><p>Novo Nordisk also continues to post competitive financial results for a pharmaceutical giant. The company's sales for the first half of the year increased by a strong 16% year over year to 154.9 billion Danish kroner ($24.2 billion).</p>
<div class="lb-trans"><p>诺和诺德在制药巨头中继续保持竞争力的财务业绩。该公司上半年的销售额同比增长了 16%，达到了 1549 亿丹麦克朗（242 亿美元）。</p>
</div><p>Further, the diabetes and obesity drug markets are rising fast due to several factors. Both conditions have skyrocketed in recent decades, and drugmakers are now developing highly innovative therapies to address them. Novo Nordisk is still at the forefront of this race. Even if the company has a smaller slice of the pie, that's not a significant problem if the pie is substantially larger.</p>
<div class="lb-trans"><p>此外，由于多种因素，糖尿病和肥胖药物市场正在快速增长。这两种疾病在最近几十年中急剧上升，制药公司现在正在开发高度创新的疗法来应对这些问题。诺和诺德仍然处于这场竞争的前沿。即使该公司在市场中的份额较小，但如果市场整体规模大幅增加，这也不是一个重大问题。</p>
</div><p>Can Novo Nordisk continue to launch innovative medicines and stay ahead of most of its peers, excluding Eli Lilly? The company's pipeline suggests that it can, and could even catch up with its eternal rival. Consider Novo Nordisk's potential triple agonist (a medicine that mimics the action of three gut hormones), UBT251.</p>
<div class="lb-trans"><p>诺和诺德能否继续推出创新药物，并在大多数竞争对手（不包括礼来）中保持领先？公司的研发管道表明它可以，甚至可能赶上其永恒的竞争对手。考虑一下诺和诺德的潜在三重激动剂（模仿三种肠道激素作用的药物）UBT251。</p>
</div><p>In a 12-week phase 1 study, UBT251 resulted in an average weight loss of 15.1% at the highest dose. The usual caveats regarding early-stage studies apply. Still, UBT251 looks promising, especially since there is no single triple agonist approved for weight loss yet. And that's just the tip of the iceberg. Novo Nordisk has several other exciting candidates through all phases of clinical development. And those that have already passed phase 3 studies, such as CagriSema, should generate massive sales for the drugmaker.</p>
<div class="lb-trans"><p>在一项为期 12 周的第一阶段研究中，UBT251 在最高剂量下平均减重 15.1%。关于早期研究的通常警告适用。然而，UBT251 看起来很有前景，特别是因为目前尚未批准任何单一的三重激动剂用于减重。这只是冰山一角。诺和诺德还有其他几个令人兴奋的候选药物正在进行各个阶段的临床开发。而那些已经通过三期研究的药物，如 CagriSema，应该为这家制药公司带来巨额销售。</p>
</div><p>According to some projections, CagriSema could rack up $15.2 billion in revenue by 2030. Ozempic and Wegovy, Novo Nordisk's current bestsellers, should also remain among the top-selling medicines in the world through the end of the decade. So, Novo Nordisk's medium-term outlook seems promising.</p>
<div class="lb-trans"><p>根据一些预测，CagriSema 到 2030 年可能会实现 152 亿美元的收入。诺和诺德目前的畅销药物 Ozempic 和 Wegovy 预计在本十年末仍将保持全球畅销药物的地位。因此，诺和诺德的中期前景似乎乐观。</p>
</div><h2>There are more reasons to buy</h2>
<div class="lb-trans"><h2>还有更多购买理由</h2>
</div><p>Novo Nordisk appeals to growth-oriented investors, but it is also a great pick for dividend seekers and bargain hunters. For those seeking income stocks, the Denmark-based drugmaker is a great choice, given its strong track record. The company's forward yield is not exceptional at 2.9% -- although that's much better than the <strong>S&amp;P 500</strong>'s average of 1.3% -- but Novo Nordisk has consistently increased its dividends over the past decade.</p>
<div class="lb-trans"><p>诺和诺德吸引了以增长为导向的投资者，但对于寻求分红和捡便宜的投资者来说也是一个不错的选择。对于那些寻求收入股票的投资者来说，这家总部位于丹麦的制药公司是一个不错的选择，考虑到其强劲的业绩记录。该公司的前瞻性收益率虽然不算特别，只有 2.9%——尽管这比 <strong>标准普尔 500</strong> 的平均水平 1.3% 要好得多——但诺和诺德在过去十年中持续增加其分红。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/139c9b8375922eacc3348b2ceba36a5b.png" alt="" original-src="https://media.ycharts.com/charts/139c9b8375922eacc3348b2ceba36a5b.png"/></p>
<p>NVO Dividend (Annual) data by YCharts</p>
<div class="lb-trans"><p>NVO 分红（年度）数据来源于 YCharts</p>
</div><p>Finally, Novo Nordisk's shares are trading at 14 times forward earnings, whereas the average for the healthcare industry is 17.3. Even with the challenges it has faced recently, Novo Nordisk's strong pipeline and lineup, solid revenue growth, and excellent prospects in diabetes and weight management make the stock highly attractive. The company's shares are changing hands for about $59, so $100 can afford you one of them.</p>
<div class="lb-trans"><p>最后，诺和诺德的股票交易价格为前瞻性收益的 14 倍，而医疗行业的平均水平为 17.3 倍。尽管最近面临挑战，诺和诺德强大的研发管道和产品组合、稳健的收入增长以及在糖尿病和体重管理方面的良好前景使得该股票极具吸引力。该公司的股票目前交易价格约为 59 美元，因此 100 美元可以购买到一股。</p>
</div>

目前用 100 美元购买的最明智的成长型股票